Retatrutide vs semaglutide — which produces better results?

Retatrutide vs semaglutide is the comparison defining the next chapter of weight loss pharmacology. Semaglutide — sold as Ozempic and Wegovy — is the medication that started the GLP-1 revolution, with millions of prescriptions worldwide and years of real-world data proving its effectiveness. Retatrutide is the experimental successor that has produced the most impressive weight loss figures ever seen in clinical trials — but without the regulatory approval, the long-term safety data, or the prescribing history that semaglutide has earned. The retatrutide vs semaglutide question is not simply “which is better” — it is “which is better for you, right now, given where the science stands.”

This guide compares retatrutide vs semaglutide across every dimension that matters: how they work, weight loss results, side effects, dosing, cost, availability, and the practical considerations that should inform your decision. The information here is based on published clinical trial data and is consistent with general weight management guidance from the NHS. This is not medical advice — consult your prescriber before starting or switching any medication.

Retatrutide vs semaglutide — at a glance

Factor	Retatrutide	Semaglutide (Ozempic/Wegovy)
Mechanism	GLP-1 + GIP + glucagon triple agonist	GLP-1 single receptor agonist
Developer	Eli Lilly	Novo Nordisk
Average weight loss	22–24% (phase 2, 48 weeks)	15–17% (phase 3, 68 weeks)
Injection frequency	Once weekly	Once weekly
Trial dose range	1 mg → 12 mg	0.25 mg → 2.4 mg
Approval status	Phase 3 trials — not approved	Fully approved (UK, EU, US)
Long-term safety data	Limited (phase 2 only)	Extensive (years of real-world use)
UK availability	Research-grade only	NHS prescription + private
Brand names	None approved (Synedica is a research pen format)	Ozempic, Wegovy

Retatrutide vs semaglutide — how they work differently

Semaglutide: one receptor, proven results

Semaglutide activates the GLP-1 receptor — a single hormonal pathway that reduces appetite, slows gastric emptying, improves insulin sensitivity, and creates the sustained calorie reduction that drives weight loss. It is the most studied GLP-1 medication in the world, with extensive phase 3 data, years of real-world prescribing, and a safety profile that has been validated across millions of patients. In the retatrutide vs semaglutide comparison, semaglutide’s advantage is certainty — you know exactly what it does, how well it works, and what the risks are.

Retatrutide: three receptors, unprecedented results

Retatrutide activates three receptors simultaneously — GLP-1, GIP, and glucagon. Each pathway contributes something distinct to weight loss. GLP-1 suppresses appetite and slows gastric emptying (the same effect as semaglutide). GIP enhances insulin sensitivity and improves fat metabolism (adding a second engine). Glucagon receptor activation increases energy expenditure, promotes active fat breakdown, and reduces liver fat — a metabolic dimension that no approved medication targets. In the retatrutide vs semaglutide comparison, retatrutide’s advantage is potency — the triple mechanism produces greater weight loss in clinical trials than any single-receptor approach.

Retatrutide vs semaglutide — weight loss results

Metric	Retatrutide (12 mg, phase 2)	Semaglutide (2.4 mg, phase 3)
Average total body weight loss	~24%	~15–17%
Patients losing >10%	~93%	~70%
Patients losing >20%	~75%	~30–35%
Average loss for 100 kg patient	~24 kg	~15–17 kg
Trial duration	48 weeks	68 weeks
Weight loss curve at end of trial	Still declining (not plateaued)	Plateauing by week 60

The retatrutide vs semaglutide weight loss comparison is striking: retatrutide at 12 mg produced approximately 7–9 percentage points more weight loss than semaglutide at maximum dose — and it achieved this in a shorter trial period, with the weight loss curve still trending downward at 48 weeks, suggesting that longer treatment could widen the gap further.

Retatrutide vs semaglutide — side effects compared

Side effect	Retatrutide (12 mg)	Semaglutide (2.4 mg)
Nausea	~45%	~40–45%
Diarrhoea	~28%	~25–30%
Constipation	~25%	~20–25%
Vomiting	~18%	~15–25%
Decreased appetite	~28%	~20%
Injection site reactions	~5%	~5–8%

The retatrutide vs semaglutide side effect profiles are broadly comparable — gastrointestinal effects dominate both medications and are most pronounced during dose escalation. The rates at maximum doses are similar enough that side effect profile alone is unlikely to be the deciding factor between the two. However, retatrutide’s glucagon receptor activation may produce additional effects not yet fully characterised — including slight increases in heart rate and changes in liver enzyme levels that were observed in the phase 2 trial without raising safety concerns. The full side effect profile of retatrutide will be clearer after phase 3 data is published.

Retatrutide vs semaglutide — dosing and titration

Phase	Retatrutide	Semaglutide (Wegovy)
Starting dose	2 mg weekly	0.25 mg weekly
Step 2	4 mg (week 5)	0.5 mg (week 5)
Step 3	8 mg (week 9)	1.0 mg (week 9)
Step 4	12 mg (week 13)	1.7 mg (week 13)
Step 5 (maintenance)	12 mg ongoing	2.4 mg (week 17)
Weeks to maintenance	~12 weeks	~16–20 weeks
Injection frequency	Once weekly	Once weekly

Both medications follow a similar titration philosophy — start low, increase monthly, reach maintenance dose within 3–5 months. Retatrutide reaches its maximum dose slightly faster (12 weeks vs 16–20 weeks) with fewer dose steps. In the retatrutide vs semaglutide comparison, the injection frequency and overall patient experience during titration are very similar. Both are subcutaneous injections that can be self-administered at home.

Retatrutide vs semaglutide — cost and availability UK

Factor	Retatrutide	Semaglutide
NHS availability	Not available	Available (strict eligibility)
Private prescription	Not available (not approved)	£150–£250/month
Research-grade	Available — vials and pen formats (e.g. Synedica pens)	Available — lyophilised vials
Regulatory status	Phase 3 trials	Fully approved
Expected approval	Late 2026 or 2027 (estimate)	Already approved

The most significant practical difference in the retatrutide vs semaglutide comparison is availability. Semaglutide is a fully approved, regulated medication available through NHS prescription (with eligibility criteria) and private clinics. Retatrutide is not approved anywhere in the world — it is only available as a research-grade compound from specialist suppliers. Patients using research-grade retatrutide do so with the understanding that the full safety and efficacy data from phase 3 trials is not yet available. This is a fundamental risk/reward consideration that every patient must weigh for themselves.

Retatrutide vs semaglutide — which is right for you?

Semaglutide may be better if:

• You want a proven, approved medication: Years of real-world data, regulatory approval, and established prescribing guidelines give semaglutide a certainty that retatrutide cannot yet match
• Your weight loss goals are moderate: If 15–17% body weight loss meets your target, semaglutide delivers this reliably for most patients
• You prefer NHS or private prescription access: Semaglutide is available through established medical channels with prescriber oversight
• You want the most safety data available: Semaglutide has the longest safety track record of any GLP-1 medication currently on the market
• Budget is a primary concern: Semaglutide is generally the more affordable option, particularly through NHS access

Retatrutide may be better if:

• You have significant weight to lose: If your goal is 20%+ body weight loss, retatrutide’s higher efficacy at maximum dose gives you a better statistical chance of reaching that target
• Semaglutide has not produced adequate results: Some patients respond poorly to single-receptor GLP-1 agonists. The triple-receptor approach of retatrutide may produce a response where semaglutide did not
• You have strong insulin resistance or metabolic syndrome: The addition of GIP and glucagon receptor activation provides metabolic benefits beyond what GLP-1 alone delivers
• You are comfortable with research-grade products: Understanding that you are using a medication with preliminary data and accepting the associated risks
• You want the most potent option available: The clinical data is clear — retatrutide produces the greatest average weight loss of any medication tested to date